These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 8847155)
1. Influence of aging on the oxidative and conjugative metabolism of propranolol. Tateishi T; Fujimura A; Shiga T; Ohashi K; Ebihara A Int J Clin Pharmacol Res; 1995; 15(3):95-101. PubMed ID: 8847155 [TBL] [Abstract][Full Text] [Related]
2. The influence of diltiazem versus cimetidine on propranolol metabolism. Tateishi T; Ohashi K; Fujimura A; Ebihara A J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547 [TBL] [Abstract][Full Text] [Related]
3. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response. Sowinski KM; Burlew BS Pharmacotherapy; 1997; 17(6):1305-10. PubMed ID: 9399616 [TBL] [Abstract][Full Text] [Related]
4. Quantitative account of propranolol metabolism in urine of normal man. Walle T; Walle UK; Olanoff LS Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169 [TBL] [Abstract][Full Text] [Related]
5. Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing. Lankford SM; Maskasame C; Bai SA Drug Metab Dispos; 1994; 22(5):776-87. PubMed ID: 7835231 [TBL] [Abstract][Full Text] [Related]
6. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites. Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909 [TBL] [Abstract][Full Text] [Related]
7. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates. Walle T; Wilson MJ; Walle UK; Bai SA Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137 [TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic interaction study of avitriptan and propranolol. Marathe PH; Greene DS; Kollia GD; Barbhaiya RH Clin Pharmacol Ther; 1998 Mar; 63(3):367-78. PubMed ID: 9542480 [TBL] [Abstract][Full Text] [Related]
9. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol. Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628 [TBL] [Abstract][Full Text] [Related]
10. Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver. Ring JA; Ghabrial H; Ching MS; Shulkes A; Smallwood RA; Morgan DJ Drug Metab Dispos; 1995 Feb; 23(2):190-6. PubMed ID: 7736910 [TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects. Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733 [TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371 [TBL] [Abstract][Full Text] [Related]
13. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441 [TBL] [Abstract][Full Text] [Related]
14. Propranolol concentrations after oral administration in term and preterm neonates. Filippi L; Cavallaro G; Fiorini P; Malvagia S; Della Bona ML; Giocaliere E; Bagnoli P; Dal Monte M; Mosca F; Donzelli G; la Marca G J Matern Fetal Neonatal Med; 2013 May; 26(8):833-40. PubMed ID: 23205867 [TBL] [Abstract][Full Text] [Related]
15. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus. Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic comparison of propranolol and atenolol in people with primary hypertension]. Telatyńska-Smieszek B Ann Acad Med Stetin; 2002; 48():367-80. PubMed ID: 14601489 [TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Wójcicki J; Jaroszynska M; Droździk M; Pawlik A; Gawrońska-Szklarz B; Sterna R Biopharm Drug Dispos; 2003 Jul; 24(5):211-8. PubMed ID: 12784321 [TBL] [Abstract][Full Text] [Related]
18. Analysis of hepatic metabolism affecting pharmacokinetics of propranolol in humans. Kiriyama A; Honbo A; Iga K Int J Pharm; 2008 Feb; 349(1-2):53-60. PubMed ID: 17765415 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. Jacobs G; Whittem T; Sams R; Calvert C; Ferguson D Am J Vet Res; 1997 Apr; 58(4):398-403. PubMed ID: 9099387 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. Aramaki S; Mori M; Nakata M; Shinohara A; Koizumi T Biol Pharm Bull; 2000 Nov; 23(11):1333-40. PubMed ID: 11085362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]